8-K: Akoya Biosciences Reports Q4 and Full Year 2024 Financial Results; Acquisition by Quanterix Pending

Akoya Biosciences announced its Q4 and full year 2024 financial results, highlighting revenue decline, gross margin improvement, operating expense reduction, and a pending acquisition by Quanterix Corporation.

Summary

• Akoya Biosciences reported a revenue of $21.3 million for Q4 2024, a 19.4% decrease compared to the prior year period.
• The decrease in revenue was primarily due to a decline in instrument revenue.
• Gross margin improved to 67.4% in Q4 2024, compared to 62.7% in the prior year period, driven by operational efficiency and product mix.
• Operating expenses decreased by 22.9% to $20.1 million in Q4 2024, due to operating leverage and efficiencies.
• The operating loss improved by 39.5% to $5.7 million in Q4 2024.
• As of December 31, 2024, Akoya had $35.0 million in cash, cash equivalents, and marketable securities.
• Full year 2024 revenue was $81.7 million, a 15.5% decrease compared to the prior year.
• Full year 2024 gross margin was 58.6%, or 61.1% non-GAAP adjusted.
• Full year 2024 operating expenses were $94.6 million, or $88.6 million non-GAAP.
• Full year 2024 loss from operations was $46.7 million, or $38.6 million non-GAAP.
• The installed base of instruments increased by 12.4% to 1,330 as of December 31, 2024.
• Total publications citing Akoya's technology increased by 49.4% to 1,733.
• Akoya announced a pending acquisition by Quanterix Corporation.
• Akoya announced a strategic product roadmap and an exclusive global license agreement with NeraCare.
• Nature Methods named spatial proteomics 'Method of the Year 2024'.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue declined, the company improved gross margins and reduced operating expenses. The pending acquisition by Quanterix is a positive development, but the lack of forward guidance adds uncertainty.

Positives

• Gross margin improved in Q4 2024 to 67.4%, driven by operational efficiency and product mix.
• Operating expenses decreased by 22.9% in Q4 2024, reflecting improved operating leverage.
• The operating loss improved by 39.5% in Q4 2024.
• The installed base of instruments increased by 12.4% to 1,330.
• Publications citing Akoya's technology increased by 49.4% to 1,733.
• Akoya is being acquired by Quanterix Corporation.
• Akoya secured an exclusive global license agreement with NeraCare for the Immunoprint test.
• Nature Methods named spatial proteomics 'Method of the Year 2024'.

Negatives

• Revenue decreased by 19.4% in Q4 2024, primarily due to a decline in instrument revenue.
• Full year 2024 revenue decreased by 15.5% compared to the prior year.
• Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases.

Risks

• The life science tools market was constrained by subdued capital equipment purchases in 2024.
• The pending acquisition by Quanterix is subject to customary closing conditions and may not be consummated.
• Akoya's ability to achieve market acceptance of its current and planned products and services is subject to risks and uncertainties.
• Akoya's ability to develop, achieve regulatory approval, and commercialize Immunoprint is subject to risks and uncertainties.

Future Outlook

In light of the pending acquisition by Quanterix Corporation, Akoya will not be hosting an earnings conference call or providing forward guidance at this time.

Management Comments

• 'Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year.'
• 'We remain optimistic about the long-term growth outlook of Akoyas leading spatial biology solutions,' said Brian McKelligon, CEO of Akoya.
• 'In 2024, Akoya achieved multiple milestones, including expanding our market-leading installed base to 1,330 instruments, launching our Manufacturing Center of Excellence to drive improvements in gross margins and the expansion of our content menu into new markets like neurobiology, and continued advancement of our clinical partnerships led by Acrivon and NeraCare.'

Industry Context

Akoya operates in the spatial biology market, which is experiencing growth and innovation, as evidenced by Nature Methods naming spatial proteomics 'Method of the Year 2024'. The acquisition by Quanterix suggests a trend towards integrated solutions in the life science tools market.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the pending acquisition by Quanterix suggests a move towards consolidation and integrated solutions, similar to trends seen with other life science companies.
• The focus on spatial biology and proteomics aligns with the broader industry trend towards personalized medicine and advanced diagnostics.

Stakeholder Impact

• Shareholders may be impacted by the pending acquisition by Quanterix.
• Employees may be affected by restructuring and facility consolidation.
• Customers may benefit from the integrated solutions resulting from the acquisition.
• Suppliers may be impacted by changes in Akoya's business strategy.

Next Steps

• Completion of the acquisition by Quanterix Corporation.
• Advancement of the strategic product roadmap.
• Development and commercialization of the Immunoprint test with NeraCare.

Key Dates